Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:STML

Stemline Therapeutics (STML) Stock Price, News & Analysis

Stemline Therapeutics logo

About Stemline Therapeutics Stock (NASDAQ:STML)

Key Stats

Today's Range
$11.83
$11.83
50-Day Range
$11.83
$11.83
52-Week Range
$3.21
$18.22
Volume
1,084 shs
Average Volume
1.52 million shs
Market Capitalization
$621.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive STML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STML Stock News Headlines

Trade These 7 Stocks Under $10 for Huge Profits
See More Headlines

STML Stock Analysis - Frequently Asked Questions

Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analysts' expectations of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and ZIOPHARM Oncology (ZIOP).

Company Calendar

Last Earnings
11/07/2019
Today
11/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:STML
Fax
N/A
Employees
92
Year Founded
N/A

Profitability

Net Income
$-76,820,000.00
Net Margins
-150.30%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$43.22 million
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$621.21 million
Optionable
Optionable
Beta
1.78
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:STML) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners